This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silverberg, S. J. Articles by Bilezikian, J. P. Search for Related Content PubMed PubMed Citation Articles by Silverberg, S. J. Articles by Bilezikian, J. P.

"Incipient" Primary Hyperparathyroidism: A "Forme Fruste" of an Old Disease

Departments of Medicine (S.J.S., J.P.B.) and Pharmacology (J.P.B.), College of Physicians and Surgeons, Columbia University, New York, New York 10032

Address all correspondence and requests for reprints to: Shonni J. Silverberg, M.D., Department of Medicine, College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032. E-mail: sjs5{at}columbia.edu.

Although primary hyperparathyroidism today is often a relatively asymptomatic disease, it has distinct biochemical and skeletal features. These features are present at diagnosis and are generally stable over time, leading to the theory of a biphasic disease course in which alterations occur during a preclinical phase. Measurement of calciotropic hormones in individuals undergoing skeletal evaluation has led to the identification of normocalcemic individuals with elevated PTH levels. We hypothesize that these patients represent the earliest manifestations of primary hyperparathyroidism

Twenty-two patients had hyperparathyroidism (94 ± 29 pg/ml) and normal corrected serum calcium levels (2.40 ± 0.02 mmol/liter). No secondary causes of hyperparathyroidism were found. PTH levels did not correlate with urinary calcium concentration, renal function, vitamin D concentrations, or bone density. The relationship between PTH and serum calcium (regression slope, +0.004) was identical in normocalcemic and hypercalcemic hyperparathyroid patients. Preferential cortical bone loss, characteristic of patients with primary hyperparathyroidism, was not seen (T-score: spine, -1.6; hip, -1.8; distal one-third radius, -1.3). In up to 12 months of observation, three patients have developed hypercalcemia, and one has had two adenomas removed.

These patients with elevated PTH levels in the absence of hypercalcemia may provide a window into this previously unrecognized stage of the disease and permit investigators to track its evolution in ways that have not heretofore been possible.

This work was supported in part by National Institutes of Health Grants NIDDK 32333 and DK60588.

Abbreviations: BMD, Bone mineral density; IRMA, immunoradiometric assay.

This article has been cited by other articles:

				S. A. Lietman, Y. Tenenbaum-Rakover, T. S. Jap, W. Yi-Chi, Y. De-Ming, C. Ding, N. Kussiny, and M. A. Levine A Novel Loss-of-Function Mutation, Gln459Arg, of the Calcium-Sensing Receptor Gene Associated with Apparent Autosomal Recessive Inheritance of Familial Hypocalciuric Hypercalcemia J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4372 - 4379. [Abstract] [Full Text] [PDF]

				G. B. Mann, Y. C. Kang, C. Brand, P. R. Ebeling, and J. A. Miller Secondary Causes of Low Bone Mass in Patients With Breast Cancer: A Need for Greater Vigilance J. Clin. Oncol., August 1, 2009; 27(22): 3605 - 3610. [Abstract] [Full Text] [PDF]

				M. R. Rubin, J. P. Bilezikian, D. J. McMahon, T. Jacobs, E. Shane, E. Siris, J. Udesky, and S. J. Silverberg The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 Years J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3462 - 3470. [Abstract] [Full Text] [PDF]

				I. Titon, A. Cailleux-Bounacer, J. P. Basuyau, H. Lefebvre, A. Savoure, and J. M. Kuhn Evaluation of a standardized short-time calcium suppression test in healthy subjects: interest for the diagnosis of primary hyperparathyroidism Eur. J. Endocrinol., September 1, 2007; 157(3): 351 - 357. [Abstract] [Full Text] [PDF]

				H. Lowe, D. J. McMahon, M. R. Rubin, J. P. Bilezikian, and S. J. Silverberg Normocalcemic Primary Hyperparathyroidism: Further Characterization of a New Clinical Phenotype J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3001 - 3005. [Abstract] [Full Text] [PDF]

				L. Gianotti, F. Tassone, F. Cesario, A. Pia, P. Razzore, G. Magro, A. Piovesan, and G. Borretta A Slight Decrease in Renal Function Further Impairs Bone Mineral Density in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3011 - 3016. [Abstract] [Full Text] [PDF]

				E. Hagstrom, E. Lundgren, J. Rastad, and P. Hellman Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur. J. Endocrinol., July 1, 2006; 155(1): 33 - 39. [Abstract] [Full Text] [PDF]

				I. Charopoulos, S. Tournis, G. Trovas, P. Raptou, P. Kaldrymides, G. Skarandavos, K. Katsalira, and G. P. Lyritis Effect of Primary Hyperparathyroidism on Volumetric Bone Mineral Density and Bone Geometry Assessed by Peripheral Quantitative Computed Tomography in Postmenopausal Women J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1748 - 1753. [Abstract] [Full Text] [PDF]

				E. M. Brown Medical Therapy of Primary Hyperparathyroidism: Are We There Yet? IBMS BoneKEy, August 1, 2005; 2(8): 5 - 8. [Full Text] [PDF]

				A. M. Parfitt Weight of Normal Parathyroid Glands in Patients with Parathyroid Adenomas J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 595 - 595. [Full Text] [PDF]

				J. P. Bilezikian and S. J. Silverberg Asymptomatic Primary Hyperparathyroidism N. Engl. J. Med., April 22, 2004; 350(17): 1746 - 1751. [Full Text] [PDF]